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ABSTRACT  26 
The heteromerization of Mu (MOP) and delta (DOP) opioid receptors has been extensively 27 
studied in heterologous systems. These studies demonstrated significant functional 28 
interaction of MOP and DOP evidenced by new pharmacological properties and intracellular 29 
signalling in transfected cells co-expressing the receptors. Due to the lack of appropriate 30 
tools for receptor visualization, such as specific antibodies, the pharmacological and 31 
functional properties of MOP-DOP heteromers in cells naturally expressing these receptors 32 
remains poorly understood. To address endogenous MOP-DOP heteromer trafficking and 33 
signalling in vivo and in primary neuronal cultures, we generated a double knock-in mouse 34 
line expressing functional fluorescent versions of DOP and MOP receptors. This mouse 35 
model has successfully been used to map the neuroanatomic distribution of the receptors 36 
and to identify brain regions in which the MOP-DOP heteromers are expressed. Here, we 37 
describe a method to quantitatively and automatically analyze changes in the subcellular 38 
distribution of MOP-DOP heteromers in primary hippocampal culture from this mouse 39 
model. This approach provides a unique tool to address specificities of endogenous MOP-40 
DOP heteromer trafficking. 41 
INTRODUCTION  42 
Opioid receptors belong to the subfamily of Class A G protein-coupled receptors (GPCRs). 43 
Four subtypes of opioid receptors mu (MOP), delta (DOP), kappa (KOP) and nociceptin 44 
(NOP) receptor respectively encoded by the OPRM1, OPRD1, OPRK1 and OPRL1 genes have 45 
been identified several decades ago (for review see [1-3]).  These seven transmembrane 46 
domain receptors are functional in a monomeric form, but can also associate among 47 
themselves to generate a  larger assembly or with different subtypes of opioids or non-opioid 48 
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receptors. In the latter case,  the new entity is called heteromer and may exhibit specific 49 
functional properties.  50 
 In the case of the opioid system, MOP and DOP functional interactions are well documented 51 
Among others, they are essential for the development of opiate tolerance [4,5]. Numerous 52 
studies indicate that co-expression of the two receptors in heterologous systems promotes 53 
the formation of MOP-DOP heteromers, which affects binding and signaling properties [6,7]. 54 
However, in spite of a growing body of evidence in favor of the presence of MOP-DOP 55 
heteromers in vivo, the molecular mechanisms underlying functional interactions between 56 
these two receptors remain poorly characterized[8]. This is mainly due to the lack of 57 
appropriate tools, especially specific antibodies.  58 
To deal with this issue and study MOP-DOP heteromers in vivo, we generated a double 59 
fluorescent knock-in mouse line co-expressing DOP and MOP receptors respectively fused to 60 
their C-terminus to the enhanced green fluorescent protein (DOP-eGFP) or mcherry (MOP-61 
mcherry). The DOP-eGFP and MOP-mCherry functional fusions allow highly specific and 62 
simultaneous visualization of endogenously expressed receptors with subcellular resolution 63 
and proved to be unique tools for neuroanatomical studies [9]. Mapping of MOP and DOP 64 
receptors in the central and peripheral nervous systems indeed revealed MOP-DOP neuronal 65 
co-expression in discrete neuronal networks essential for survival such as the nociceptive 66 
pathway (see also mouse brain atlas at http://mordor.ics-mci.fr/). Specific targeting using the 67 
fluorescent tags also revealed MOP-DOP physical proximity in the hippocampus providing 68 
strong rationale for the existence of endogenous MOP-DOP heteromers [9]. In addition, the 69 
double fluorescent knock-in mice represent unique tools to explore the dynamics of this 70 
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complex under physiological or pathological conditions and to characterize the functional 71 
impact of MOP-DOP heteromers in the central and peripheral nervous system.  72 
In this chapter, we describe optimized conditions for visualization of endogenous MOP-DOP 73 
heteromers in primary hippocampal neurons obtained from the double fluorescent knock-in 74 
mice. We also provide a protocol for automatic quantitative analysis of confocal images with 75 
an open source software to determine changes in receptor subcellular localization. This 76 
method allowed MOP-DOP heteromers monitoring and specific determination of their 77 
intracellular fate upon pharmacological activation.  78 
MATERIAL AND METHODS 79 
1. Animals  80 
Double knock-in mice co-expressing fluorescent DOP and MOP receptors were obtained by 81 
crossing previously generated DOP-eGFP and MOP-mcherry knock-in mice. Briefly, DOP-82 
eGFP knock-in mice expressing the delta opioid receptor fused to its C-terminus to the eGFP 83 
were generated by homologous recombination by inserting the eGFP cDNA into exon 3 of 84 
the delta opioid receptor gene, in frame and 5′ from the stop codon [10]. MOP-mcherry 85 
knock-in mice expressing the mu opioid receptor fused to its C-terminus to the red 86 
fluorescent protein mCherry were generated by homologous recombination following a 87 
procedure similar to the one used for DOR-eGFP knock-in mice [9]. The construct transfected 88 
into ES cells comprised a Gly-Ser-Ile-Ala-Thr linker followed by the cDNA sequence 89 
encoding the fluorescent protein (eGFP or mcherry). For subsequent clone selection, a 90 
resistance gene was included that corresponded to neomycin flanked by loxP sites for DOP-91 
eGFP or to hygromycin flanked by FRT sites for MOP-mcherry (Figure 1). The resistance 92 
gene was removed by microinjection of a plasmid expressing the recombinase. Blastocysts 93 
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were implanted in pseudo gestant BalbC females. Chimeric mice were crossed with C57Bl6/J 94 
mice to obtain F1 heterozygous generation. Heterozygous animals were crossed to generate 95 
mice homozygous for Oprd1-eGFP or Oprm1-mcherry that are fertile and develop normally. 96 
Double knock-in animals were obtained by crossing the single knock-in mouse lines. The 97 
genetic background of all mice was C57/BL6/J: 129svPas (50:50 %).  98 
Mice were housed in animal facility under controlled temperature (21 ± 2 °C) and humidity 99 
(45 ± 5 %) on a 12-h dark–light cycle with food and water ad libitum. All experiments were 100 
performed in accordance to the European legislation (directive 2010/63/EU acting on 101 
protection of laboratory animals) and the local ethical committee.   102 
2. Primary hippocampal culture 103 
2.1. Material and reagents:  104 
• Double knock-in new born mice pups (P0-P3).  105 
• 70% ethanol solution 106 
• MilliQ water (autoclaved, or sterile filtered 0.22µm).  107 
• Borate buffer (see setup and procedures)  108 
• Poly-L-lysine hydrobromide (Sigma cat. No. P2623) 109 
• 13 mm coverslips (Sigma, cat. no. P6407) coated with Poly-L-lysine (see setup and 110 
procedure) 111 
• 24-well sterile culture plates (Falcon cat. no. 353047). 112 
• Pasteur pipets (flamed at the extremity, cotton plugged and autoclaved).  113 
• Hibernate minus phenol red (BrainBits SKU: HAPR) 114 
• Papain (Worthington, cat. no. LS003126) 115 
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• Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5g glucose (GIBCO, cat. no. 116 
71966-029) 117 
• Neurobasal A (GIBCO, cat. no. A13710-01) 118 
• Foetal Calf Serum FCS heat inactivated. Caution: test several batches to determine the 119 
best one for your culture conditions. 120 
• Glutamax™ (GIBCO, cat. no. 35050061) 121 
• L-glutamine (GIBCO, cat. no. 25030081 ) 122 
• Penicillin-streptomycin (P/S) (cat. no. 15140122) 123 
• DNAse (Sigma cat. no. DN25).  124 
• B27 supplement (GIBCO, cat. no. 17504044) 125 
• Trypan blue solution (Sigma, cat. no. T8154) 126 
• Paraformaldehyde 32% solution diluted to 4% before use (see setup and reagents).  127 
• Phosphate buffer saline (PBS). (Sigma-Aldrich, cat. no. P5493)  128 
• Cell strainer 70µm (Falcon, cat. no. 352350) 129 
2.2. Setup and procedures 130 
2.2.1. Borate buffer: dissolve boric acid 1,24g and Sodium tetraborate (borax) 1,9g in 400ml 131 
MilliQ H2O. pH should be 8.4. Sterile filter (0.22µm) before use. Caution: borax is a hazardous 132 
substance, manipulate cautiously and eliminate waste according to the safety rules fixed by your 133 
institution/government.   134 
2.2.2. Coverslips sterilisation and coating: put coverslips in a 100-mm petri dish, sterilise 135 
in 70% ethanol during 2 h under gentle agitation, let dry completely under laminar flow, and 136 
transfer to culture plates. Rinse once with MilliQ water. Coat coverslips with poly-L-lysine 137 
25µg/ml final concentration in borate buffer; incubate at 37°C for 2h to overnight. Rinse 3 138 
times with sterile water and pre-warm in DMEM medium. Coated coverslips may be 139 
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prepared several days before use, dried in the laminar flow hood and kept sealed at 4°C for 140 
up to 1 month. 141 
2.2.3. Dissection medium: Prepare 5 mL of of ice cold Hibernate supplemented with 1X P/S 142 
and 0.5nM glutamax per animal and transfer 0.5 mL dissection medium in a 15-mL 143 
centrifugation tube per animal (2 hippocampi).  144 
2.2.4. Enzyme solution: prior to dissection, prepare a fresh solution of Papain at 40U/mL 145 
concentration in Hibernate medium, incubate 5 minutes at 37°C in a water bath then keep on 146 
ice until use. Prepare 0.5 mL per animal (2 hippocampi).  147 
2.2.5. Plating medium: Prepare 12 mL DMEM medium supplemented with 4.5 g/l glucose 148 
+ 10% heat inactivated FCS + 2mM Glutamine + Pen/strep) per animal on the day of use.  149 
2.2.6. Growing medium: Prepare 12 mL Neurobasal medium supplemented with 2% B27, 150 
2mM glutamax, 0.5mM glutamine and 1X P/S per animal on the day of use.  151 
2.2.7. Phosphate-buffered saline (PBS): prepare 1L 1X PBS working solution from 10X 152 
stock solution by diluting with MilliQ water. Check the pH and adjust to 7.4 with 1M HCl or 153 
1M NaOH solutions if needed. Sterile filter 0.22µm and keep at 4°C for up to 6 months.  154 
2.2.8. Fixation solution: dilute paraformaldehyde (PFA) 32% solution to 4% final 155 
concentration in PBS 0.1M, adjust pH to 7.4 if needed. Prepare 500µl per well for use in 24-156 
well plate. Keep up to 5 days at 4°C and up to 6 months at -20°C. Caution: PFA a hazardous 157 
highly toxic substance, manipulate under flow hood and eliminate waste according to the safety rules 158 
fixed by your institution/government.     159 
2.3. Dissection and culture procedures 160 
2.3.1. Dissection and cell dissociation  161 
Decapitate pups. Transfer the head in a 33mm petri dish with 1.5 mL ice cold dissection 162 
medium and isolate the brain. Place the isolated brain in a new 33mm petri dish with 1.5mL 163 
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ice cold dissection medium. Remove the meninges, dissect to isolate the two hippocampi and 164 
keep them in 0.5mL dissection solution in a 15 mL-tube in ice. Add 0.5 mL of papain solution 165 
per tube to 0.5 mL dissection medium (1mL final / 2 hippocampi). Place tubes in a water bath 166 
at 37°C for 30 minutes with gentle shaking every 5-10 minutes. 5-10 minutes before digestion 167 
ends, add DNase at a final concentration of 1mg/mL.  168 
Remove papain solution by decantation, add 1mL of Hibernate, and triturate with Pasteur 169 
pipet until the tissue is completely dissociated (about 15 to 20 times up-and-down are 170 
sufficient) (see note 1). Centrifuge at 1000g for 5 minutes at 22°C. Remove the supernatant, 171 
add 1mL plating medium to resuspend cells (3 to 5 gentle up-and-down with Pasteur pipet). 172 
Filter the cell suspension through a 70µm-cell strainer to remove any residual aggregates. 173 
Count cells by diluting 20µl of cell suspension in 80µl of 1:10 Trypan blue solution diluted in 174 
PBS. Place 20µl of this solution in a cell counting chamber and count cells excluding Trypan 175 
blue (viable cells) only.  176 
2.3.2. Plating and feeding  177 
Prewarm poly-L-Lysine coated plates in DMEM medium at 37°C. Remove DMEM and plate 178 
cells in 24-well plates at a density of 80 000 to 100 000 cells per well in a final volume of 500 179 
µL.  180 
Incubate in a humid incubator at 37°C and 5% CO2 and allow cells to adhere to the bottom of 181 
plates during one hour. Remove the plating medium by aspiration, rinse once with 500µl of 182 
prewarmed Neurobasal A medium, then add 500µl of growing medium and return back to 183 
the incubator. Let cells grow during at least twelve days with half of the medium replaced 184 
every four to five days.  185 
3. Processing and pharmacological treatments 186 
9 
 
Pharmacological treatments should be realized between DIV 12 and DIV 15 after plating (see 187 
note 2). Ligands are added in a volume not exceeding 10% of the culture medium volume. 188 
Incubate cells during the appropriate time. At the end of the pharmacological treatment, 189 
remove the plate from the incubator and immediately place on ice, carefully aspirate the 190 
medium and wash twice with ice cold sterile filtered PBS. Remove PBS and add 500µL of 191 
PFA 4% in ice cold PBS and incubate during 20 minutes on ice. Remove PFA and rinse twice 192 
with ice cold PBS and proceed to immunostaining or keep sealed with Parafilm in 500µL PBS 193 
at 4°C up to 30 days (see note 3). 194 
4. Immunocytofluorescence (ICF):  195 
4.1. Material and reagents 196 
• Phosphate buffer Saline 0.1M, pH 7.4. 197 
• Normal Goat Serum (NGS) (Sigma cat. no. S26) 198 
• Tween20 (Euromedex cat. no. 2001-B) 199 
• Primary and secondary antibodies (see table 1) 200 
• ProLong™ Gold Antifade Mounting medium (Molecular Probes cat. no. P36935). 201 
• DAPI (Sigma cat. no. D9542) 202 
• Finepoint Forceps (Rubis Switzerland cat.no.1K920) 203 
• Microscope glass slides.  204 
4.2. Setup and reagents  205 
4.2.1. PBS Tween 20 solution (PBST): add 0.2% (V:V) of Tween 20 solution to 1X PBS 206 
solution (see section 1.2.7) , mix vigorously to complete dissolution and keep at 4°C. Bring at 207 
room temperature before use.   208 
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4.2.2. Blocking solution: add 5% of Normal Goat Serum (NGS) to the PBST solution. 209 
Prepare the day of use.    210 
4.3. Method 211 
Incubate fixed cells in 250 µL of blocking solution for one hour under gentle agitation at 212 
room temperature (20-22°C). Then remove the blocking solution by aspiration and incubate 213 
2h at RT or overnight at 4°C with primary antibodies in blocking solution (250µL/well) 214 
under gentle agitation. Wash three times in PBST and incubate for two hours protected from 215 
light with specific secondary antibodies diluted in blocking solution (Table 1) (250µL/well). 216 
Wash three times in PBST, incubate 5 minutes in DAPI solution (1µg/mL in PBS) for nuclei 217 
staining and then wash three times in PBS followed by 1 wash in MilliQ H2O. Remove 218 
coverslips from wells with finepoint Forceps, let coverslips dry completely at room 219 
temperature protected from light and mount on glass slides with ProLong™ Gold Antifade 220 
mounting medium. Keep for up to one year at -20° protected from light.   221 
5. Confocal microscope  222 
Images were acquired with a laser-scanning confocal microscope Leica SP5 using 63X /NA 223 
1.4 oil immersion lens and X5 numerical zoom. The Pinhole was adjusted to 1 airy Unit and 224 
the gain was adjusted without offset for each filter on a specific scanning plan allowing 225 
specific acquisition without saturation. Image acquisition was performed according to 226 
Nyquist parameters in XY with an average frame of 3 in a sequential scan mode to avoid 227 
cross talk between different wavelengths. Z-stacks were obtained by scanning the whole 228 
neuron thickness with step of 1 µm in z.   229 
6. Image analysis with ICY open source software  230 
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Confocal images were analyzed with ICY software (http://icy.bioimageanalysis.org/). 231 
Quantification was performed on a single plane extracted from a z-stack. The analysis 232 
combined two sequential steps. The first one consists in isolating each neuron to define 233 
regions of interest (ROI). The second one involves the detection of the spots in each channel 234 
and the determination of the amount of co-localisation in each ROI.  235 
6.1. ROI definition  236 
Each neuron was carefully delineated using the “free-hand area” tool. This initial ROI is 237 
filled with the “fill holes in ROI” plugin to define the total cell area (ROI total). ROIs were then 238 
processed to generate two ROIs corresponding to the cell periphery and the cytoplasm 239 
(detailed protocol available online http://icy.bioimageanalysis.org/). Based on staining in basal 240 
conditions, we estimated that most of the plasma membrane staining was found over an 8 241 
pixels thickness. Therefore, we automatically eroded with the “Erode ROI” plugin the ROI 242 
total by 8 pixels and subtracted this new ROI (ROI cyto) to ROI total to obtain a ROI 243 
corresponding to the cell periphery (ROI peri).  244 
6.2. Spots detection and co-localisation  245 
To detect specific signal in each ROI, we used the “spot detector” plugin which rely on the 246 
wavelet transform algorithm [11]. By carefully setting the sensitivity threshold and the scale 247 
of objects to detect, it allows detection of spots even in images with low signal to noise ratio. 248 
In our conditions, the sensitivity threshold was fixed between 50 and 60 % and the scale of 249 
objects set at 2 (pixel size 3) for mu and delta receptors. Once parameters were defined, 250 
images were images were processed with the tool “protocol” in Icy which is a graphical 251 
interface for automated image processing. Data including the number of spots detected in 252 
each channel and ROIs, the number of co-localized objects and the ROI area were 253 
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automatically collected in excel files. Objects were considered co-localized if the distance of 254 
their centroid was equal to or less than 3 pixels. The protocol is available online 255 
(NewColocalizer with binary and excel output v1_batch.xml). To obtain histograms we calculated 256 
object densities for each receptor reported to the surface of each ROI. Membrane to 257 
cytoplasm density ratios were calculated to illustrate the subcellular distribution of each 258 
receptor. The extend of co-localisation was calculated according to the following formula for 259 
each ROI [%	𝑐𝑜𝑙𝑜𝑐𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛 = 100𝑋	( 01210324567	89:	3;7	<9:	1=>60?5	∑(	76?60?67	89:	3;7	<9:	1=>60?5))].  260 
7. Statistical analysis 261 
Statistical analyses were performed with Graphpad Prism V7 software (GraphPad, San 262 
Diego, CA). Normality of the distributions and homogeneity of the variances were checked 263 
before statistical comparison to determine appropriate statistical analysis. In our case, data 264 
were not normally distributed and the non-parametric Mann Witney test was used to 265 
compare receptor densities in the plasma membrane and cytoplasm in basal conditions or 266 
after agonist treatment. The extend of receptor co-localisation was compared using two-way 267 
ANOVA with repeated measures followed by post-hoc Sidak’s test for multiple 268 
comparisons. Basal group was compared to agonist treated group (first factor) within 269 
cytoplasm and plasma membrane localisation (second factor).  270 
RESULTS AND DISCUSSION 271 
In this chapter, we have presented an optimized method for monitoring the subcellular 272 
distribution of endogenous MOP and DOP receptors. To this aim, we combined the use of a 273 
genetically modified mouse line co-expressing functional fluorescently tagged receptors, 274 
optimized primary neuronal culture protocol and automatic quantitative analysis of confocal 275 
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images with an open source software.  Importantly, the image analysis procedure can be 276 
easily implemented in any laboratory since data processing does not require extensive 277 
mathematical developments or program writing with specialized software.  278 
Individual distribution of MOP and DOP receptors 279 
High magnification confocal images analyzed as single focal plan revealed discontinuous 280 
and punctate distributions for DOP-eGFP and MOP-mCherry that were predominantly 281 
located at the cell surface in basal conditions (Figure 2-A). Images also revealed a perinuclear 282 
cytoplasmic localization of both receptors that likely correspond to receptor stock in the 283 
endoplasmic reticulum. These observations were consistent with data from the literature 284 
describing a predominant and membrane localization of DOP [10,12] and MOP [13] but also 285 
substantial localization in perikarya [10]. 286 
Quantification using the ICY software indicated a higher density of fluorescent objects at the 287 
cell surface for both MOP and DOP receptors (Figure 2-B) that was three times higher 288 
compared to the cytoplasm (Fig. 2-C). Activation by the MOP-DOP agonist CYM51010 let to 289 
the appearance of high intensity punctate structures in the cytoplasmic and a dramatic 290 
decrease in the plasma membrane labelling of both receptors (figure 2-A). Accordingly, the 291 
ratio corresponding to the density of fluorescent objects density at the plasma membrane 292 
compared to the cytoplasm dropped dramatically from 3 to 1 for both MOP and DOP 293 
receptors which supports internalization of the two receptors in vesicle-like structures.  294 
These results are in agreement with previous reports using the density of fluorescence to 295 
estimate changes in DOPeGFP subcellular distribution in vivo. In these studies, the ratio of 296 
fluorescence density between the plasma membrane and cytoplasm was about 1.5 in basal 297 
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conditions and significantly decreased following agonist stimulation [10,14]. We therefore 298 
tested our quantification method using images of DOR-eGFP neurons in the hippocampus 299 
acquired with similar parameters in confocal microscopy. Using the protocol described 300 
above, we found that the density in DOP-eGFP objects under basal conditions was around 3 301 
similar to our results in primary neuronal cultures. We also established that this value 302 
corresponded to a ratio in fluorescence density between the plasma membrane and the 303 
cytoplasm of about 1.7, similar to previously reported ratios [10]. Moreover, we quantified 304 
the ratio of fluorescence density between the plasma membrane and the cytoplasm using the 305 
set of images used in Erbs et al 2016, and calculated a similar increase of about 10% in DOP-306 
eGFP expression at the plasma membrane after chronic morphine treatment in the neurons 307 
of the hippocampus [15]. Altogether, these results fully validate the quantification method 308 
developed using ICY software. 309 
Co-localization of MOP and DOP receptors and detection of MOP-DOP 310 
heteromers 311 
Our analysis revealed substantial colocalization of MOP and DOP associated signals under 312 
basal conditions. In fact, more than 22% of the MOP and DOP objects were co-localized 313 
within the plasma membrane whereas cytoplasmic colocalization was fairly low (around 314 
10%) (Figure 2-D). After selective MOP-DOP activation with the agonist CYM51010, the 315 
cytoplasmic colocalization was increased by 87% to reach 18.7%. A two-fold decrease in the 316 
percentage of MOP-DOP colocalization within the plasma membrane was also observed 317 
after CYM51010 treatment (Figure 2-D). These observations support a view in which MOP 318 
and DOP receptors remain associated upon specific activation of the heteromers and 319 
undergo common intracellular fate. 320 
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It is however important to note, that due to the resolution limit of confocal microscopy, 321 
MOP-DOP physical interaction has to be assessed by other experimental approaches such as 322 
co-localization in electron microscopy or disruption of the physical contact by a 323 
transmembrane peptide. The latter has been successfully performed for MOP-DOP receptors 324 
in vivo. Indeed, a peptide corresponding to the MOP TM 1 or to the DOP second intracellular 325 
loop in fusion with the cell transduction domain of the human immunodeficiency virus 326 
(HIV) TAT protein interfered with MOP-DOP co-immunoprecipitation [16-18]. The recently 327 
described proximity ligation assay [19] provides high spatial resolution and represents 328 
another attractive option to address physical proximity. 329 
In addition, the resolution of the images did not enable to distinguish the pool of receptors 330 
associated to the plasma membrane from receptors located in the sub-membrane 331 
compartment which represents another limitation of our analysis.  Total internal reflection 332 
fluorescence microscopy (TIRFM) would be required to differentiate the two compartments 333 
and precisely monitor the first steps in receptor internalization.  334 
MOPmcherry-DOPeGFP co-localisation studies could also be combined with identification of 335 
the intracellular compartments using specific antibodies. This would enable for fine mapping 336 
of the receptors in the vesicular structures and cellular compartments and would provide 337 
detailed information on the intracellular fate of MOP-DOP heteromers.  338 
CONCLUSION 339 
Double knock-in mice represent unique tools to investigate endogenous MOP-DOP 340 
neuroanatomical distribution but also to explore functional dynamics in physio-pathological 341 
conditions. As described here, the use of double fluorescent knock-in mice combined with 342 
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confocal imaging and ICY software analyses enables easy quantification of receptor sub-343 
cellular distribution and co-localisation, hence specific MOP-DOP trafficking. Importantly, 344 
the field of application of the method described here is not restricted to the study of MOP-345 
DOP heteromers but can be applied to address the heteromerization of any other pair of 346 
GPCRs. Moreover, the analysis with the ICY software is not restricted to the study of 347 
receptors but is widely applicable to monitor the co-localisation of any two objects detected 348 
independently and can be applied to any type of high-resolution images. 349 
NOTES 350 
1- Cell dissociation is a critical step; if the trituration is too gentle, the tissue will not 351 
dissociate, if too vigorous cells will break. 352 
2- Because re-expression of DOP-eGFP and MOP-mCherry is only detectable from day 353 
in vitro (DIV) 10 in primary neurons, pharmacological treatments should be 354 
performed between DIV12 and DIV15 to ensure full expression of the receptors.  355 
3- Paraformaldehyde fixation decreases the fluorescence intensity of eGFP and mCherry 356 
and amplification by immunostaining is recommended. The DOP-eGFP construct can 357 
also be used for ex vivo real-time imaging of receptor internalization by confocal 358 
microscopy [10]. However, due to the low expression level of endogenous MOP 359 
receptors and their weak expression at the plasma membrane in basal conditions, 360 
real-time monitoring of MOP-mcherry remains presently below the detection limit.  361 
ACKNOWLEDGMENTS  362 
17 
 
The authors would like to acknowledge the financial support of the Fondation pour la 363 
Recherche Médicale (LPA20140129364). L. Derouiche was the recipient of an IDEX post-364 
doctoral fellowship of the University of Strasbourg. 365 
CONFLICT OF INTEREST 366 
The authors declare no conflict of interest   367 
REFERENCES  368 
1. Charbogne P, Kieffer BL, Befort K (2014) 15 years of genetic approaches in vivo for 369 
addiction research: Opioid receptor and peptide gene knockout in mouse models of drug 370 
abuse. Neuropharmacology 76 Pt B:204-217. doi:10.1016/j.neuropharm.2013.08.028 371 
2. Pasternak GW (2014) Opioids and their receptors: Are we there yet? 372 
Neuropharmacology 76 Pt B:198-203. doi:10.1016/j.neuropharm.2013.03.039 373 
3. Civelli O (2008) The orphanin FQ/nociceptin (OFQ/N) system. Results Probl Cell 374 
Differ 46:1-25. doi:10.1007/400_2007_057 375 
4. Ong EW, Cahill CM (2014) Molecular Perspectives for mu/delta Opioid Receptor 376 
Heteromers as Distinct, Functional Receptors. Cells 3 (1):152-179. doi:10.3390/cells3010152 377 
5. Gendron L, Mittal N, Beaudry H, Walwyn W (2015) Recent advances on the delta 378 
opioid receptor: from trafficking to function. Br J Pharmacol 172 (2):403-419. 379 
doi:10.1111/bph.12706 380 
6. Gomes I, Ijzerman AP, Ye K, Maillet EL, Devi LA (2011) G protein-coupled receptor 381 
heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol 79 382 
(6):1044-1052. doi:10.1124/mol.110.070847 383 
18 
 
7. Fujita W, Gomes I, Devi LA (2014) Revolution in GPCR signalling: opioid receptor 384 
heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol 171 (18):4155-385 
4176. doi:10.1111/bph.12798 386 
8. Massotte D (2015) In vivo opioid receptor heteromerization: where do we stand? Br J 387 
Pharmacol 172 (2):420-434. doi:10.1111/bph.12702 388 
9. Erbs E, Faget L, Scherrer G, Matifas A, Filliol D, Vonesch JL, Koch M, Kessler P, 389 
Hentsch D, Birling MC, Koutsourakis M, Vasseur L, Veinante P, Kieffer BL, Massotte D 390 
(2015) A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical 391 
networks. Brain Struct Funct 220 (2):677-702. doi:10.1007/s00429-014-0717-9 392 
10. Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Laustriat D, Cao YQ, Basbaum AI, 393 
Dierich A, Vonesh JL, Gaveriaux-Ruff C, Kieffer BL (2006) Knockin mice expressing 394 
fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo. 395 
Proc Natl Acad Sci U S A 103 (25):9691-9696. doi:10.1073/pnas.0603359103 396 
11. Olivo-Marin JC (2002) Extraction of spots in biological images using multiscale 397 
products. Pattern Recogn 35 (9):1989-1996. doi:Pii S0031-3202(01)00127-3 Doi 10.1016/S0031-398 
3203(01)00127-3 399 
12. Cahill CM, McClellan KA, Morinville A, Hoffert C, Hubatsch D, O'Donnell D, 400 
Beaudet A (2001) Immunohistochemical distribution of delta opioid receptors in the rat 401 
central nervous system: evidence for somatodendritic labeling and antigen-specific cellular 402 
compartmentalization. J Comp Neurol 440 (1):65-84 403 
13. Trafton JA, Abbadie C, Marek K, Basbaum AI (2000) Postsynaptic signaling via the 404 
[mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious 405 
stimulation. J Neurosci 20 (23):8578-8584 406 
19 
 
14. Faget L, Erbs E, Le Merrer J, Scherrer G, Matifas A, Benturquia N, Noble F, 407 
Decossas M, Koch M, Kessler P, Vonesch JL, Schwab Y, Kieffer BL, Massotte D (2012) In vivo 408 
visualization of delta opioid receptors upon physiological activation uncovers a distinct 409 
internalization profile. J Neurosci 32 (21):7301-7310. doi:10.1523/JNEUROSCI.0185-12.2012 410 
15. Erbs E, Faget L, Ceredig RA, Matifas A, Vonesch JL, Kieffer BL, Massotte D (2016) 411 
Impact of chronic morphine on delta opioid receptor-expressing neurons in the mouse 412 
hippocampus. Neuroscience 313:46-56. doi:10.1016/j.neuroscience.2015.10.022 413 
16. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, Li Q, Yang H, Luo J, Li ZY, 414 
Wang Q, Lu YJ, Bao L, Zhang X (2011) Facilitation of mu-opioid receptor activity by 415 
preventing delta-opioid receptor-mediated codegradation. Neuron 69 (1):120-131. 416 
doi:10.1016/j.neuron.2010.12.001 417 
17. Kabli N, Martin N, Fan T, Nguyen T, Hasbi A, Balboni G, O'Dowd BF, George SR 418 
(2010) Agonists at the delta-opioid receptor modify the binding of micro-receptor agonists to 419 
the micro-delta receptor hetero-oligomer. Br J Pharmacol 161 (5):1122-1136. 420 
doi:10.1111/j.1476-5381.2010.00944.x 421 
18. Xie WY, He Y, Yang YR, Li YF, Kang K, Xing BM, Wang Y (2009) Disruption of 422 
Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid receptor: 423 
impaired receptor function and attenuated morphine antinociceptive tolerance. J Neurosci 29 424 
(11):3551-3564. doi:10.1523/JNEUROSCI.0415-09.2009 425 
19. Dasiel O. Borroto-Escuela  BH, Miles Woolfenden , Luca Pinton , Antonio Jiménez-426 
Beristain , Julia Ofl ijan , Manuel Narvaez , Michael Di Palma , Kristin Feltmann , Stfano 427 
Sartini , Patrizia Ambrogini , Francisco Ciruela , Riccardo Cuppini , and Kjell Fuxe (2016) In 428 
Situ Proximity Ligation Assay to Study and Understand the Distribution and Balance of 429 
20 
 
GPCR Homo- and Heteroreceptor Complexes in the Brain. Neuromethods, vol 110 Springer 430 
Science+Business Media New York edn. doi:DOI 10.1007/978-1-4939-3064-7_9 431 
  432 
TABLE 1: Primary and secondary antibodies 433 
Antigen  Antibody Supplier reference Dilution 
eGFP Chicken IgY AVES-GFP1020 1/1000 
mCherry Rabbit IgG Clontech-632496 1/1000 
Chicken IgY Goat anti chicken Alexa Fluor 488 Molecular Probes-A11039 1/2000 
Rabbit IgG Goat anti rabbit Alexa Fluor 594 Molecular Probes-A11012 1/2000 
 434 
FIGURE LEGENDS 435 
Figure 1:  Double Knock-in DOP-eGFP/MOP-mCherry mouse engineering. A) 436 
Construction of the DOP-eGFP mouse. A cDNA sequence corresponding to the eGFP cDNA, 437 
and the FRT flanked neomycine (neo) cassette was inserted by homologous recombination 438 
(HR) into the Oprd1 locus. HR was followed Cre recombinase treatment in ES cells. B) 439 
Construction of the MOP-mcherry mouse. A cDNA sequence corresponding mCherry 440 
cDNA, and the loxP flanked hygromycine (hygro) cassette were inserted by HR to the Oprm1 441 
locus. HR was followed by FRT recombinase treatment in ES cells. (C) Double knock-in mice 442 
were obtained by crossing homozygote DOP-eGFP and MOP-mCherry mice.  443 
Figure 2: MOP-DOP heteromer visualisation and quantification. A) Representative 444 
confocal images illustrating MOP-mcherry and DOP-eGFP co-localisation in basal conditions 445 
21 
 
or after treatment during 60 minutes with the MOP-DOP agonist CYM51010 400nM. Scale 446 
bar: 5µm. B) Image quantification with ICY software illustrating each receptor distribution. 447 
In basal conditions, MOP and DOP densities are significantly higher in the plasma 448 
membrane compared to cytoplasm. Mann Witney test, *p-value <0.05. CYM51010 treatment 449 
for 60 minutes led to changes in receptor subcellular distribution with no more statistical 450 
difference in receptor densities between the plasma membrane and cytoplasm (Mann Witney 451 
test, p-value > 0.05). C) Changes in receptors distribution. Plasma membrane to cytoplasm 452 
ratio of MOP or DOP spots densities in basal conditions or after with 400nM CYM51010 for 453 
60 minutes reflects receptor redistribution. Mann Witney test, ****p-value <0.001; **** p-value 454 
<0.0001. D) Quantification of MOP-DOP co-localisation upon agonist activation with 400nM 455 
CYM51010 for 60 minutes reveals MOP-DOP co-internalisation. Two-way ANOVA with 456 
repeated measures, post-hoc Sidak’s test. *p-value <0.05 for basal cytoplasm vs CYM51010 457 
cytoplasm; **p-value <0.01 for basal membrane vs CYM51010 membrane. ### p-value <0.001 458 
for basal membrane vs basal cytoplasm; NS: p-value >0.05 for CYM51010 membrane vs 459 
CYM51010 cytoplasm. 460 
 461 
Adapted from Erbs et al 2015 Brain Struc funct. 
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